VU Venture Partners — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
EnClear Therapies develops precision drug delivery technology targeting the central nervous system for patients with CNS diseases including neuro-oncology, neurodegenerative disorders, and autoimmune conditions.
BiotechDigital HealthMedical DevicesCambridge, US
Jonathan Fleming(Director)Jason Camm(Director)Kasper Roet(Director)Anthony DePasqua(Executive Officer, Director)
Figure develops general-purpose humanoid robots designed for deployment in workforce and home environments.
AI & Machine LearningHardwareRoboticsSunnyvale, US
Lee Randaccio(Executive Officer)Dana Berlin(Executive Officer)Brett Adcock(Executive Officer, Director)Logan Berkowitz(Executive Officer)Colby Adcock(Director)Peter Welinder(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.